Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Zusätzlich bieten wir Ihnen CYP2C19 Kits (19) und CYP2C19 Proteine (3) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 33 products:
Cow (Bovine) Polyclonal CYP2C19 Primary Antibody für WB - ABIN2777003
Ji, Olson, Zhang, Hildebrandt, Wang, Ingle, Fredericksen, Sellers, Miller, Dixon, Brauch, Eichelbaum, Justenhoven, Hamann, Ko, Brüning, Chang-Claude, Wang-Gohrke, Schaid, Weinshilboum: Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms. in Cancer research 2008
REVIEW: CYP2C19 and CYP2D6 (zeige CYP2D6 Antikörper) genotypes in Pacific peoples
PON1 (zeige PON1 Antikörper) and CYP2C19 polymorphisms were associated with lower clopidogrel responsiveness in this sample. Despite differences in CYP2C19 polymorphisms across white and non-white patients, genetic admixture by itself was not able to identify clopidogrel hyporesponsiveness.
The study showed that the CYP1A2 (zeige CYP1A2 Antikörper) (-163C>A) Rs762551 C/C genotype was associated with an increased risk of age-related macular degeneration.
Genetic testing of CYP2C19 may help in prescribing a dose according to genetic makeup and represent the initial steps towards the development of diagnostic tests and therapeutic strategies that will substantially improve human health.
rs4244285 of CYP2C19 have the main effects on coronary heart disease risk.
The poor metabolizer (PM) group had the lowest metabolic ratio and exhibited the highest area under the curve (AUC) for omeprazole among the CYP2C19 phenotype groups.
The carriage of the cytochrome P450 (zeige CYP Antikörper) CYP2C19 681A allele rather than platelet receptor gene polymorphisms increased extent of platelet aggregation induced by dual antiplatelet therapy in patients with Coronary heart disease .
coadministration, voriconazole AUC and Cmin decreased by 33% and 39% respectively, in CYP2C19 extensive-metabolizers, whereas voriconazole Cmax and AUC increased 4.4-fold and 5.6-fold respectively, in poor-metabolizers
individuals with both the CYP2C19*2 allele and hypertension are at high risk of Clopidogrel Resistance during anti-thrombosis therapy.
NXT (zeige NXT1 Antikörper) leaded to a significant enhancement of the CYP2C19 catalytic activity in PXR (zeige NR1I2 Antikörper)-transfected HepG2 cells
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P450 2C
, (R)-limonene 6-monooxygenase
, (S)-limonene 6-monooxygenase
, (S)-limonene 7-monooxygenase
, S-mephenytoin 4-hydroxylase
, cytochrome P-450 II C
, cytochrome P450 2C19
, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19
, cytochrome P450-11A
, cytochrome P450-254C
, flavoprotein-linked monooxygenase
, mephenytoin 4'-hydroxylase
, mephenytoin 4-hydroxylase
, microsomal monooxygenase
, xenobiotic monooxygenase